With just 10% of therapeutic programs successfully moving from first toxicity dose to market, drug developers are on a constant hunt for new tricks to put the odds in their favor. Strategies abound, from biomarker-guided patient selection to deeper regulatory engagement. But big pharma executives and an academic expert weighing the challenge at the BIO International Convention said June 14 they see another tool slowly gaining traction with the potential to decrease timelines and boost chances for approval: in-silico modeling.
Meta Pharmaceuticals Inc. has raised $15 million in seed and pre-series A rounds in six months for the pipeline and AI platform development. Shenzhen, China-based Meta Pharma plans to use the new funds to support its three candidates to enter clinical trials, as well as the development of its Meta-map platform for pipeline expansion.
China will continue to ramp up volume-based procurement (VBP) policies that bring down drug and device prices for public hospitals with volume. Governmental agencies at the local and national levels coordinate drug prices via government-organized procurement programs that include VBP and pricing negotiations for inclusion on the National Reimbursable Drug List.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association Congress, including: Ascentage, Canbridge, Daiichi Sankyo, Iaso, Innovent Biologics.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Brii, Immunome, Innocare, Kazia, Keymed, Medicinova, Merck, Moderna, Ridgeback, Rigel, Takeda, Tevogen.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aslan, Aurigene Discovery Technologies, Chromadex, Cyanvac, Emergent Biosolutions, Ferring, Gritstone, I-Mab, Janssen, Johnson & Johnson, Kazia, Multitude, Olema, Oncusp, Pfizer, Qualigen.
RSS
